Ratings by BofA Securities (Alec Stranahan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/20/2026 | ProQR Therapeutics N.V. | PRQR | New Coverage | Buy (N/A) |
2.22 (2.16) |
-2.7% | Details | |
| 8/19/2026 | Moderna | MRNA | Upgrade | Neutral (Underperform) |
62.96 (147.10) |
133.64% | Details | |
| 8/14/2026 | Candel Therapeutics Inc. | CADL | Maintain | Neutral (N/A) |
|
Details | ||
| 8/14/2026 | Erasca Inc | ERAS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/14/2026 | Perspective Therapeutics Inc | CATX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/13/2026 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2026 | Hutchison China MediTech Ltd. | HCM | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2026 | TG Therapeutics | TGTX | Maintain | Underperform (N/A) |
|
Details | ||
| 7/7/2026 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 6/12/2026 | Avalo Therapeutics Inc. | AVTX | New Coverage | Buy (N/A) |
13.67 (19.45) |
42.28% | Details | |
| 6/4/2026 | Erasca Inc | ERAS | Upgrade | Neutral (Underperform) |
13.18 (15.87) |
20.41% | Details | |
| 5/18/2026 | Candel Therapeutics Inc. | CADL | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2026 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2026 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 4/28/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2026 | Erasca Inc | ERAS | Maintain | Underperform (N/A) |
|
Details | ||
| 4/13/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2026 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2026 | WAVE Life Sciences | WVE | New Coverage | Buy (N/A) |
13.33 (4.76) |
-64.29% | Details | |
| 2/3/2026 | Akoustis Technologies | AKTS | New Coverage | Buy (N/A) |
21.98 (26.27) |
19.52% | Details | |
| 1/9/2026 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2026 | Xencor, Inc. | XNCR | Maintain | Neutral (N/A) |
|
Details | ||
| 1/7/2026 | TG Therapeutics | TGTX | Maintain | Underperform (N/A) |
|
Details | ||
| 1/7/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2026 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2026 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2026 | Hutchison China MediTech Ltd. | HCM | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2026 | Erasca Inc | ERAS | Maintain | Underperform (N/A) |
|
Details | ||
| 10/17/2025 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2025 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2025 | Xencor, Inc. | XNCR | Downgrade | Neutral (Buy) |
8.55 (26.57) |
210.76% | Details | |
| 9/3/2025 | Candel Therapeutics Inc. | CADL | Downgrade | Neutral (Buy) |
5.86 (12.98) |
121.5% | Details | |
| 9/3/2025 | Erasca Inc | ERAS | Downgrade | Underperform (Buy) |
1.60 (13.18) |
723.75% | Details | |
| 8/20/2025 | Novavax | NVAX | Downgrade | Underperform (Neutral) |
9.52 (10.15) |
6.62% | Details | |
| 8/4/2025 | TG Therapeutics | TGTX | Maintain | Underperform (N/A) |
|
Details | ||
| 8/4/2025 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 6/5/2025 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2025 | Y-mAbs Therapeutics | YMAB | Downgrade | Underperform (Neutral) |
4.82 (8.61) |
78.63% | Details | |
| 4/10/2025 | Novavax | NVAX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/4/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2025 | BioXcel Therapeutics | BTAI | Maintain | Underperform (N/A) |
|
Details | ||
| 2/11/2025 | Hutchison China MediTech Ltd. | HCM | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2025 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2025 | Candel Therapeutics Inc. | CADL | New Coverage | Buy (N/A) |
7.80 (12.98) |
66.41% | Details | |
| 1/7/2025 | BioXcel Therapeutics | BTAI | Downgrade | Underperform (Neutral) |
0.57 (0.11) |
-80.7% | Details | |
| 12/12/2024 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2024 | Alector Inc. | ALEC | Downgrade | Underperform (Neutral) |
2.52 (2.47) |
-1.98% | Details | |
| 11/25/2024 | Perspective Therapeutics Inc | CATX | Downgrade | Neutral (Buy) |
3.00 (3.07) |
2.33% | Details | |
| 11/25/2024 | Editas Medicine | EDIT | Upgrade | Buy (Underperform) |
2.37 (3.06) |
29.11% | Details | |
| 7/25/2024 | Perspective Therapeutics Inc | CATX | New Coverage | Buy (N/A) |
12.82 (3.00) |
-76.6% | Details | |
| 7/16/2024 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2024 | Novavax | NVAX | Upgrade | Neutral (Underperform) |
4.47 (9.52) |
112.98% | Details | |
| 2/28/2024 | Spring Works Therapeutics | SWTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2024 | Erasca Inc | ERAS | Downgrade | Neutral (Buy) |
2.16 (15.87) |
634.72% | Details | |
| 1/5/2024 | Revolution | RVMD | Upgrade | Buy (Neutral) |
28.03 (207.71) |
641.03% | Details | |
| 11/15/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/15/2023 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/25/2023 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 5/19/2023 | Xencor, Inc. | XNCR | New Coverage | Buy (N/A) |
26.05 (26.57) |
2% | Details | |
| 5/15/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/19/2023 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 12/29/2022 | TG Therapeutics | TGTX | Maintain | Underperform (N/A) |
|
Details | ||
| 12/15/2022 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2022 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
| 12/15/2022 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2022 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2022 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2022 | Novavax | NVAX | Maintain | Underperform (N/A) |
|
Details | ||
| 12/2/2022 | Y-mAbs Therapeutics | YMAB | Downgrade | Neutral (Buy) |
4.50 (4.82) |
7.11% | Details | |
| 12/1/2022 | Spring Works Therapeutics | SWTX | New Coverage | Buy (N/A) |
24.18 (46.99) |
94.33% | Details | |
| 10/10/2022 | Novavax | NVAX | Maintain | Underperform (N/A) |
|
Details | ||
| 5/20/2022 | TG Therapeutics | TGTX | New Coverage | Underperform (N/A) |
6.04 (55.93) |
825.99% | Details | |
| 5/20/2022 | Revolution | RVMD | New Coverage | Neutral (N/A) |
15.16 (207.71) |
1270.12% | Details | |
| 5/20/2022 | Turning Point Therapeutics Inc. | TPTX | New Coverage | Buy (N/A) |
35.36 (76.01) |
114.96% | Details | |
| 5/3/2022 | Hutchison China MediTech Ltd. | HCM | Maintain | Buy (N/A) |
|
Details | ||
| 1/18/2022 | Krystal Biotech | KRYS | New Coverage | Buy (N/A) |
62.28 (367.67) |
490.35% | Details | |
| 11/17/2021 | NextCure Inc. | NXTC | Maintain | Underperform (N/A) |
|
Details | ||
| 5/7/2021 | Y-mAbs Therapeutics | YMAB | Upgrade | Buy (Neutral) |
28.65 (8.61) |
-69.95% | Details | |
| 1/15/2021 | Esperion Therapeutics | ESPR | Downgrade | Neutral (Buy) |
26.75 (3.18) |
-88.11% | Details | |
| 1/15/2021 | NextCure Inc. | NXTC | Downgrade | Underperform (Neutral) |
13.07 (6.99) |
-46.52% | Details | |
| 1/15/2021 | Y-mAbs Therapeutics | YMAB | Downgrade | Neutral (Buy) |
49.98 (28.65) |
-42.68% | Details | |
| 10/7/2020 | Y-mAbs Therapeutics | YMAB | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2020 | MeiraGTx Holdings plc | MGTX | New Coverage | Buy (N/A) |
13.33 (13.88) |
4.13% | Details | |
| 1/14/2020 | NextCure Inc. | NXTC | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2019 | Neon Therapeutics | NTGN | Downgrade | Neutral (Buy) |
1.88 (3.07) |
63.3% | Details |
